Hydrea (Hydroxycarbamide)

Hydrea is indicated for the management of several blood‑related conditions where reduction of abnormal cell proliferation is required.

• Sickle cell disease to reduce the frequency of painful crises.
• Chronic myelogenous leukemia (CML) as part of disease‑modifying therapy.
• Polycythemia vera to control elevated red blood cell mass.
• Essential thrombocythemia to lower platelet counts.
• Myeloproliferative neoplasms not otherwise specified, to achieve cytoreduction.
• Certain solid tumor protocols where hydroxycarbamide is used off‑label for its antiproliferative effect.

• Hydroxycarbamide interferes with DNA synthesis by inhibiting the enzyme ribonucleotide reductase, which is essential for converting ribonucleotides to deoxyribonucleotides. This inhibition lowers the intracellular pool of deoxyribonucleotides, slowing DNA replication and cell division, particularly in rapidly proliferating hematopoietic cells. The resulting cytoreductive effect helps control abnormal cell growth in the indicated disorders. By limiting the supply of building blocks for DNA, hydroxycarbamide also induces cell cycle arrest in the S phase, contributing to its therapeutic activity.

Hydrea may cause a range of adverse reactions, varying from mild to potentially serious. Patients should report any new or worsening symptoms promptly.

Common

• Nausea or vomiting, often transient and manageable with anti‑emetics.
• Fatigue and generalized weakness that may affect daily activities.
• Decreased white blood cell count (leukopenia), increasing infection risk.
• Skin rash or discoloration, sometimes pruritic.

Serious

• Severe bone marrow suppression leading to pancytopenia, which may require transfusion.
• Acute renal impairment, indicated by rising creatinine levels.
• Life‑threatening allergic reactions such as anaphylaxis with airway swelling.

Before initiating Hydrea, several precautionary considerations should be reviewed to ensure safe use.

• Baseline complete blood count and renal function tests are required.
• Monitor blood counts regularly during therapy to detect cytopenias early.
• Use caution in patients with pre‑existing liver disease.
• Avoid use during pregnancy unless benefits outweigh risks; discuss contraception.
• Assess for history of hypersensitivity to hydroxycarbamide or related compounds.
• Adjust dose in patients with impaired renal function.
• Inform healthcare providers of any upcoming surgeries or invasive procedures.

Hydrea can interact with other medicines, affecting its efficacy or safety profile.

Avoid

• Concurrent use with strong myelosuppressive agents (e.g., chemotherapy) that may exacerbate bone‑marrow toxicity.
• Combination with nephrotoxic drugs (e.g., aminoglycosides) that increase risk of renal impairment.

Use with caution

• Anticoagulants (e.g., warfarin) as hydroxycarbamide may alter bleeding risk.
• Allopurinol, which can increase hydroxycarbamide plasma levels.
• Live vaccines, because immunosuppression may reduce vaccine effectiveness.
• Drugs that affect hepatic metabolism (e.g., azole antifungals) may modify drug clearance.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) as they may increase gastrointestinal toxicity.